3.37
-0.025(-0.74%)
Currency In USD
| Previous Close | 3.39 |
| Open | 3.32 |
| Day High | 3.37 |
| Day Low | 3.3 |
| 52-Week High | 152 |
| 52-Week Low | 2.88 |
| Volume | 3,745 |
| Average Volume | 560,330 |
| Market Cap | 5.95M |
| PE | -0.17 |
| EPS | -19.74 |
| Moving Average 50 Days | 8.12 |
| Moving Average 200 Days | 26.55 |
| Change | -0.03 |
Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality
GlobeNewswire Inc.
Dec 19, 2024 1:30 PM GMT
Autonomix Medical, Inc. Biotech/Med Device executive Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing
Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025
GlobeNewswire Inc.
Dec 05, 2024 1:30 PM GMT
First-in-class catheter-based sensing technology designed to sense neuronal signals that indicate pain or disease and destroy those nerves at the source Company expects to submit an Investigational Device Exemption (“IDE”), and if approved, will comm
Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option
GlobeNewswire Inc.
Nov 25, 2024 9:00 PM GMT
THE WOODLANDS, TX, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the closing of its previo